Combination Chemotherapy — Multi-drug cancer treatment

Combination chemotherapy is an established systemic treatment approach involving the simultaneous or scheduled administration of multiple cytotoxic drugs. Each chosen agent generally possesses a distinct mechanism of action and acts at different phases of the cell division cycle. For instance, an alkylating agent that damages cellular DNA may be paired with an antimetabolite that disrupts DNA synthesis.

Regimens are carefully formulated so that individual medications do not have completely overlapping toxicities. This allows oncologists to administer each drug at or near its full therapeutic dose without creating intolerable side effects for a single organ system. Protocols are frequently designated by acronyms derived from the combined drug names, such as FOLFOX or CHOP.

This strategy is a cornerstone of modern medical oncology because tumours are biologically complex and adaptable. Single-agent therapies frequently lead to treatment resistance, where surviving cells learn to bypass the drug's effects. Combination therapy delivers a more decisive therapeutic blow, improving the chances of achieving disease remission, preventing recurrence, or prolonging survival in both curative and palliative cancer care plans.

Before and during combination chemotherapy, patients undergo full blood counts, liver function tests, and renal profiles to assess organ fitness. Biomarker testing—such as testing for DPD enzyme deficiency prior to fluoropyrimidines, or screening for TPMT activity—helps prevent severe toxicities. Tumour tissue may also be evaluated for genomic alterations to select the most appropriate combination.

Combination chemotherapy is used widely across numerous malignancies. It is standard in treating haematological cancers, such as Hodgkin and non-Hodgkin lymphomas, leukemias, and multiple myeloma. It is also extensively utilised in solid tumours, including advanced breast, colorectal, ovarian, lung, and pancreatic cancers, as well as testicular germ cell tumours.

Prescribing combination chemotherapy requires rigorous scheduling, often delivered in repeating cycles followed by rest intervals. If a patient experiences significant toxicity, oncologists can adjust doses or swap a single agent while maintaining the rest of the protocol. It is also frequently integrated alongside modern targeted therapies, immunotherapies, or sequential radiotherapy.